Your browser doesn't support javascript.
loading
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes.
Coratti, Giorgia; Carmela Pera, Maria; Montes, Jacqueline; Scoto, Mariacristina; Pasternak, Amy; Bovis, Francesca; Sframeli, Maria; D'Amico, Adele; Pane, Marika; Albamonte, Emilio; Antonaci, Laura; Lia Frongia, Anna; Mizzoni, Irene; Sansone, Valeria A; Russo, Massimo; Bruno, Claudio; Baranello, Giovanni; Messina, Sonia; Dunaway Young, Sally; Glanzman, Allan M; Duong, Tina; de Sanctis, Roberto; Stacy Mazzone, Elena; Milev, Evelin; Rohwer, Annemarie; Civitello, Matthew; Darras, Basil T; Bertini, Enrico; Day, John; Muntoni, Francesco; De Vivo, Darryl C; Finkel, Richard S; Mercuri, Eugenio.
Afiliação
  • Coratti G; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Carmela Pera M; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Montes J; Departments of Rehabilitation and Regenerative Medicine and Neurology, Columbia University Irving Medical Center, New York, USA.
  • Scoto M; Dubowitz Neuromuscular Centre, UCL Institute of Child Health & Great Ormond Street Hospital, London, United Kingdom.
  • Pasternak A; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Bovis F; Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy.
  • Sframeli M; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
  • D'Amico A; Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Pane M; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Albamonte E; Neurorehabilitation Unit, University of Milan, Neuromuscular Omnicentre Clinical Center, Niguarda Hospital, Milan, Italy.
  • Antonaci L; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Lia Frongia A; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Mizzoni I; Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Sansone VA; Neurorehabilitation Unit, University of Milan, Neuromuscular Omnicentre Clinical Center, Niguarda Hospital, Milan, Italy.
  • Russo M; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
  • Bruno C; Center of Experimental and Translational Myology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Baranello G; Dubowitz Neuromuscular Centre, UCL Institute of Child Health & Great Ormond Street Hospital, London, United Kingdom.
  • Messina S; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
  • Dunaway Young S; Department of Neurology, Stanford University, Palo Alto, CA, USA.
  • Glanzman AM; Department of Physical Therapy, Children's Hospital of Philadelphia, Philadelphia, USA.
  • Duong T; Department of Neurology, Stanford University, Palo Alto, CA, USA.
  • de Sanctis R; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Stacy Mazzone E; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Milev E; Dubowitz Neuromuscular Centre, UCL Institute of Child Health & Great Ormond Street Hospital, London, United Kingdom.
  • Rohwer A; Dubowitz Neuromuscular Centre, UCL Institute of Child Health & Great Ormond Street Hospital, London, United Kingdom.
  • Civitello M; St. Jude Children's Research Hospital, Memphis, USA.
  • Darras BT; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Bertini E; Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Day J; Department of Neurology, Stanford University, Palo Alto, CA, USA.
  • Muntoni F; Dubowitz Neuromuscular Centre, UCL Institute of Child Health & Great Ormond Street Hospital, London, United Kingdom; NIHR Great Ormond Street Hospital Biomedical Research Centre, London, United Kingdom.
  • De Vivo DC; Departments of Rehabilitation and Regenerative Medicine and Neurology, Columbia University Irving Medical Center, New York, USA.
  • Finkel RS; St. Jude Children's Research Hospital, Memphis, USA.
  • Mercuri E; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. Electronic address: eugeniomaria.mercuri@unicatt.it.
Neuromuscul Disord ; 32(1): 36-42, 2022 01.
Article em En | MEDLINE | ID: mdl-34980538
The aim of the study was to establish 24-month changes in a large cohort of type II and III spinal muscular atrophy (SMA) patients assessed with the Revised Upper Limb Module (RULM), a tool specifically developed to assess upper limb function in SMA. We included 107 patients (54 type II and 53 type III) with at least 24-months follow up. The overall RULM 24-month changes showed a mean decline of -0.79 points. The difference between baseline and 24 months was significant in type II but not in type III patients. There was also a difference among functional subgroups but not in relation to age. Most patients had 24-month mean changes within 2 points, with 23% decreasing more than 2 points and 7% improving by >2 points. Our results suggest an overall progressive decline in upper limb function over 24 months. The negative changes were most notable in type II, in non-ambulant type III and with a different pattern of progression, also in non-sitter type II. In contrast, ambulant type III showed relative stability within the 24-month follow up. These findings will help in the interpretation of the real world data collected following the availability of new therapeutic approaches.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Atrofia Muscular Espinal / Extremidade Superior Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Neuromuscul Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Atrofia Muscular Espinal / Extremidade Superior Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Neuromuscul Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália